Trop-2 expression as a biomarker of response to sacituzumab govitecan in patients with HER2-negative metastatic breast cancer: A pilot study
Cancer Treatment and Research Communications · 2025
DOI: 10.1016/j.ctarc.2025.100954 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Treatment and Research Communications, 2025. Verfasst von Alexis LeVee und 6 weiteren Autor:innen. Beteiligte Einrichtung: City of Hope Comprehensive Cancer Center, Duarte, CA, United States. Electronic address: alevee@coh.org. Hauptthemen laut MEDLINE: Breast Neoplasms, Antigens, Neoplasm, Cell Adhesion Molecules, Biomarkers, Tumor. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Institutes of Health, National Institutes of Health National Cancer Institute.
Abstract (Originalsprache)
BACKGROUND: Sacituzumab govitecan (SG) is an anti-Trop-2 antibody-drug conjugate (ADC) approved for use in HER2-negative metastatic breast cancer (MBC). This study explores whether Trop-2 expression serves as a biomarker of excellent response versus non-response to sacituzumab govitecan (SG) in HER2-negative MBC. METHODS: Trop-2 expression was determined from patients with HER2-negative MBC categorized as non-responders and excellent responders to SG. Excellent response was defined by a complete or partial response and a progression-free survival (PFS) greater than the median of the cohort. Non-response was defined by progressive disease within 3 months. Trop-2 expression was determined based on percentage of cells staining and a histochemical score (H-score). RESULTS: Of the 15 patients with HER2-negative MBC (8 non-responders/7 excellent responders), the median Trop-2 expression rate was 100 % in both groups (p=0.3). H-score was also similar between the groups, with a median H-score of 270 (range 25-300) in non-responders and 280 (range 120-290) in responders (p=1.0). Lower Trop-2 percent expression was associated with shorter PFS (hazard ratio [HR]: 0.014; 95 % CI, 0-0.52; p=0.018), although Trop-2 expression by H-score was not predictive of PFS (HR: 0.994; 95 % CI, 0.987-1.002; p=0.12). One non-responder had an H-score of 25, which may represent a complete lack of Trop-2 expression. DISCUSSION: In this study, Trop-2 expression did not predict excellent response versus non-response to SG in patients with HER2-negative MBC. Low Trop-2 expression, as determined by percentage staining, was predictive of shorter PFS, although the same association was not observed using the H-score. A complete lack of Trop-2 expression may predict SG ineffective, which requires further investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- City of Hope Comprehensive Cancer Center, Duarte, CA, United States. Electronic address: alevee@coh.org.
- City of Hope Comprehensive Cancer Center, Duarte, CA, United States.
Förderung
- National Institutes of Health
- National Institutes of Health National Cancer Institute
Zitieren
APA
LeVee, A., Wong, M., Ruel, N., Schmolze, D., Han, M., Mortimer, J., & Wei, C. (2025). Trop-2 expression as a biomarker of response to sacituzumab govitecan in patients with HER2-negative metastatic breast cancer: A pilot study. Cancer Treatment and Research Communications. https://doi.org/10.1016/j.ctarc.2025.100954
Vancouver
LeVee A, Wong M, Ruel N, Schmolze D, Han M, Mortimer J, et al. Trop-2 expression as a biomarker of response to sacituzumab govitecan in patients with HER2-negative metastatic breast cancer: A pilot study. Cancer Treatment and Research Communications. 2025. doi:10.1016/j.ctarc.2025.100954
BibTeX
@article{LeVee2025,
author = {LeVee, Alexis and Wong, Megan and Ruel, Nora and Schmolze, Daniel and Han, Min and Mortimer, Joanne and Wei, Christina},
title = {Trop-2 expression as a biomarker of response to sacituzumab govitecan in patients with HER2-negative metastatic breast cancer: A pilot study},
journal = {Cancer Treatment and Research Communications},
year = {2025},
doi = {10.1016/j.ctarc.2025.100954}
}
EUVIMED